Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus

• Main Authors: Tim R. Cressey, Linda Harrison, Jullapong Achalapong, Prateep Kanjanavikai, Orada Patamasingh Na Ayudhaya, Prateung Liampongsabuddhi, Thitiporn Siriwachirachai, Chaiwat Putiyanun, Pornnapa Suriyachai, Camlin Tierney, Nicolas Salvadori, Dujrudee Chinwong, Luc Decker, Yardpiroon Tawon, Trudy V. Murphy, Nicole Ngo-Giang-Huong, George K. Siberry, Gonzague Jourdain
• Format: Journal
• Published: 2018
• Subjects: Medicine; Pharmacology, Toxicology and Pharmaceutics
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85057201918&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/62978
• Institution: Chiang Mai University

Copyright © 2018 American Society for Microbiology. We assessed tenofovir exposure during pregnancy and postpartum in hepatitis B virus (HBV)-infected HIV-uninfected women receiving tenofovir disoproxil fumarate (TDF) to prevent mother-to-child transmission of HBV. Data from 154 women who received TDF within a randomized controlled trial were included. Individual plasma tenofovir exposures (area under the concentration-time curve from 0 to 24 h [AUC0-24]) were estimated using a population pharmacokinetic approach. The estimated geometric mean tenofovir AUC0-24 was 20% (95% confidence interval [95% CI], 19 to 21%) lower during pregnancy than during postpartum; this modest reduction in the absence of HBV transmission suggests that no dose adjustment is needed.